Tags : Hypereosinophilic Syndromes

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab)

Tuba Khan April 4, 2019

Shots: The P-II (NCT02130882) study involves assessing of Fasenra (benralizumab,30mg, q4w) vs PBO in 20 patients with HES who had at least 1,000 eosinophils/µL of blood The P-II (NCT02130882) clinical […]readmore

Tags : Hypereosinophilic Syndromes

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Hypereosinophilic Syndromes

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company